

NOW THE WORLD'S #1 SELLING DERMAL FILLER BRAND¹


**25%
MORE***
with 1.0 mL

JUVÉDERM[®] XC: Experience 25% MORE* Clinically Relevant[†] HA per Syringe


MORE CLINICALLY RELEVANT,[†] HIGHLY CROSS-LINKED HA²

Highly cross-linked HA	~ 90% ²
Uncross-linked HA	~ 10% ²
Total HA	24 mg/mL

JUVÉDERM[®] XC (NOW! 1.0 mL)



EXPERIENCE 25% MORE* WITH 1.0 ML



*Vs the JUVÉDERM[®] XC 0.8 cc syringe.

[†]Clinically relevant HA is defined as highly cross-linked hyaluronic acid.

A Brief Description of Indications for Use, Contraindications, Warnings, Precautions, and Adverse Events for JUVÉDERM[®] Injectable Gel

Indication: In the United States, JUVÉDERM[®] injectable gel (including JUVÉDERM[®] Ultra, JUVÉDERM[®] Ultra Plus, JUVÉDERM[®] Ultra XC, and JUVÉDERM[®] Ultra Plus XC) is indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).

Contraindications: JUVÉDERM[®] injectable gel should not be used in patients who have severe allergies marked by a history of anaphylaxis or history or presence of multiple severe allergies. JUVÉDERM[®] should not be used in patients with a history of allergies to Gram-positive bacterial proteins. JUVÉDERM[®] Ultra XC and JUVÉDERM[®] Ultra Plus XC should not be used in patients with a history of allergies to lidocaine.

Warnings: JUVÉDERM[®] injectable gel should not be injected into blood vessels. If there is an active inflammatory process or infection at specific injection sites, treatment should be deferred until the underlying process is controlled.


 **Juvéderm[®] XC**
EXPERIENCE SMOOTH. EXPECT MORE.

Please see additional important safety information inside.

JUVÉDERM® XC: Expect MORE From the Market Leader

MORE of the same SMOOTH FLOW

The *first* **smooth-consistency** HA gel that flows easily and consistently.



Proprietary HYLACROSS™ technology creates random shapes and sizes to form a smooth-consistency gel.

The smooth-consistency gel of the JUVÉDERM® injectable gel brand vs the granular-consistency gel of another HA filler, left: 2.4x magnification (0.05 cc).

The clinical significance of the difference has not been established.


MORE of the same SMOOTH COMFORT

The HA filler formulated with powdered lidocaine to **reduce pain** during and after treatment.^{2,3,*}

DURING treatment **92%***

of JUVÉDERM® XC injectable gel patients had a REDUCTION in pain of at least 1 point on an 11-point Visual Analog Scale (VAS) (N = 72).^{2,*}



AFTER treatment^{3,*}



^a 47% with JUVÉDERM® XC, relative to 64% with JUVÉDERM®
^b 71% with JUVÉDERM® XC, relative to 83% with JUVÉDERM®

MORE of the same SMOOTH OUTCOMES


The *first* and *only* FDA-approved HA filler that **lasts up to 1 year** with initial treatment.^{4,†}



^aWrinkle Assessment Scale.

81% of subjects treated with JUVÉDERM® Ultra Plus injectable gel for severe NLFs maintained ≥ 1-grade improvement beyond 1 year in a subset analysis (n = 16).⁵

Clinical trial results with JUVÉDERM® Ultra Plus



Unretouched photos; clinical trial participant.⁵ Individual results may vary.

*When compared to the nonlidocaine JUVÉDERM® formulations.


†This includes all JUVÉDERM® injectable gel formulations. Most subjects acquired optimal correction at initial treatment.

JUVÉDERM[®] XC: Expect High Performance and MORE Loyalty

EXPECT HIGH COHESIVITY

JUVÉDERM[®] XC has the **highest cohesivity** compared to other HA gels, based on in vitro testing.²

EXPECT SIGNIFICANT LIFT CAPACITY THROUGH HIGH COHESIVITY⁷



JUVÉDERM[®]

Restylane[®]


- The cohesive nature of JUVÉDERM[®] XC allows the gel to hold its shape and structure under stress⁷

The clinical significance of this difference has not been established.

EXPECT MORE PATIENT LOYALTY WITH JUVÉDERM[®]

JUVÉDERM[®] has **significantly higher** patient retention rates.^{8,†}

Retention Rates Based on Patients at the Third Visit



^aStatistically significant difference.

*Vs the JUVÉDERM[®] XC 0.8 cc syringe.

†Which dermal filler was injected in the nasolabial folds at this patient's initial visit? Which dermal filler was injected at this patient's third visit?

A Brief Description of Indications for Use, Contraindications, Warnings, Precautions, and Adverse Events for JUVÉDERM[®] Injectable Gel (continued)


Precautions: The safety of JUVÉDERM[®] for use during pregnancy, in breastfeeding females, or in patients under 18 years has not been established. The safety and effectiveness of JUVÉDERM[®] injectable gel for the treatment of areas other than facial wrinkles and folds (such as lips) have not been established in controlled clinical studies. Patients who are using substances that can prolong bleeding, such as aspirin or ibuprofen, as with any injection, may experience increased bruising or bleeding at injection site. Patients should inform their physician before treatment if they are using these types of substances. As with all skin-injection procedures, there is a risk of infection. JUVÉDERM[®] should be used with caution in patients on immunosuppressive therapy, or therapy used to decrease the body's immune response, as there may be an increased risk of infection. The safety of JUVÉDERM[®] in patients with a history of excessive scarring (eg, hypertrophic scarring and keloid formations) and pigmentation disorders has not been studied. If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment with JUVÉDERM[®] injectable gel, or if JUVÉDERM[®] is administered before the skin has healed completely after such a procedure, there is a possible risk of an inflammatory reaction at the treatment site.

Please see additional important safety information on the last page.

JUVÉDERM® XC: Expect MORE From the Market Leader

FILL moderate facial wrinkles
with JUVÉDERM® Ultra XC


MODERATE



JUVÉDERM® Ultra XC (2.4 mL)

VOLUMIZE severe facial folds
with JUVÉDERM® Ultra Plus XC

SEVERE



JUVÉDERM® Ultra Plus XC (2.4 mL)

Unretouched photos of paid JUVÉDERM® XC injectable gel patients. **Individual results may vary.**

EXPECT MORE WITH JUVÉDERM® XC:

- **25% MORE*** clinically relevant[†] HA in 2 versatile 1.0 mL formulations
- **MORE** of the same smooth flow, **MORE** of the same smooth comfort, **MORE** of the same smooth outcomes
 - Highest cohesivity compared to other HA gels, based on in vitro testing²
- **MORE** brand loyalty with JUVÉDERM®⁸

*Vs the JUVÉDERM® XC 0.8 cc syringe.

[†]Clinically relevant HA is defined as highly cross-linked hyaluronic acid.

A Brief Description of Indications for Use, Contraindications, Warnings, Precautions, and Adverse Events for JUVÉDERM® Injectable Gel (continued)

Adverse events: The most commonly reported side effects are temporary injection-site redness, swelling, pain/tenderness, firmness, lumps/bumps, and bruising. Most side effects are mild or moderate in nature, and their duration is short lasting (7 days or less).

Important: For full safety information, please visit www.juvederm.com or call Allergan Product Support at 1-877-345-5372.

CAUTION: Rx only.

For directions for use (DFU), please visit www.juvederm.com/dfu.



1. Data on file, Allergan, Inc.; Worldwide Dermal Facial Filler Market Overview, Q2 2011. 2. Data on file, Allergan, Inc. 3. Weinkle SH, Bank DE, Boyd CM, Gold MH, Thomas JA, Murphy DK. A multi-center, double-blind, randomized controlled study of the safety and effectiveness of JUVÉDERM® injectable gel with and without lidocaine. *J Cosmet Dermatol.* 2009;8(3):205-210. 4. Pinsky MA, Thomas JA, Murphy DK, Walker PS; for JUVÉDERM® vs ZYPLAST® Nasolabial Fold Study Group. JUVÉDERM® injectable gel: A multicenter, double-blind, randomized study of safety and effectiveness. *Aesthetic Surg J.* 2008;28(1):17-23. 5. Lupo MP, Smith SR, Thomas JA, Murphy DK, Beddingfield FC 3rd. Effectiveness of JUVÉDERM® Ultra Plus dermal filler in the treatment of severe nasolabial folds. *Plast Reconstr Surg.* 2008;121(1):289-297. 6. Pinsky MA, Thomas JA, Murphy DK, Walker PS. JUVÉDERM® injectable gel: A multicenter, double-blind, randomized study of safety and effectiveness. Poster presented at: Annual Meeting of the American Society for Aesthetic Plastic Surgery; April 19-24, 2007; New York, NY. 7. Borrell M, Leslie DB, Tezel A. Lift capabilities of hyaluronic acid fillers. *J Cosmet Laser Ther.* 2011;13(1):21-27. 8. Data on file, Allergan, Inc., September 9, 2011; Dermal Filler Chart Retention Study.